Related Experiment Video
Updated: Sep 20, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
Published on: August 18, 2023
Concordance Between a Mohs Micrographic Surgeon and Dermatopathologist on Margin Status for Melanoma In Situ and the
Arianna F Yanes1, Amina Bougrine2, Adriano Piris2
1Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Background:
Few studies have examined the concordance between Mohs surgeons and dermatopathologists' interpretation of margin status during Mohs micrographic surgery (MMS) for melanoma in situ (MIS).
Objective:
The objectives of this study were to determine the concordance between a Mohs surgeon and dermatopathologist on margin status for MIS and to analyze the role of immunohistochemical stains during Mohs surgery.
Materials And Methods:
This was a prospective study at 1 academic center of patients undergoing Mohs surgery for MIS. The Mohs surgeon and dermatopathologist independently examined the margins and completed surveys on the usefulness of H&E and immunohistochemical stains in each case. Six-year follow-up data on tumor recurrence and metastasis were collected.
Results:
The surgeon and dermatopathologist agreed on margin status in 95% of cases (95% confidence interval: 0.84-0.99). The dermatopathologist found H&E alone to be the most useful stain for the first stage of MMS, while the Mohs surgeon found the combination of H&E and SOX10 most useful. This study is limited by the use of only 2 physicians.
Conclusion:
There was a high concordance between the Mohs surgeon and dermatopathologist on MIS margin status. Immunohistochemical stains were more useful for the Mohs surgeon.
More Related Videos
09:58DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma
Published on: June 6, 2025
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024